30 YEARS OF
THERAKOS ECP IMMUNOMODULATION^TM
TREATING GvHD

Celebrating three decades of THERAKOS ECP Immunomodulation^TM for GvHD patients

This year, we are delighted to offer you a whole range of educational initiatives dedicated to furthering knowledge in GvHD.

2024 programme and announcements

EBMT 2024 - Industry Symposium

30 years of ECP in GvHD: Recommendations for the treatment of cGvHD

GvHD Hub - Supported through an unrestricted educational grant by Therakos – Mallinckrodt
Hall 5 | Sunday, April 14, 16:30 – 18:00

View Symposium >

EBMT 2024 - Nurse Symposium

30 Years of ECP – Patient-centered therapy using Therakos ECP technology, then, now and in the future

Hall 1 | Tuesday, April 16, 13:00 – 14:00

View Symposium >

COSTEM 2024: THERAKOS MEET THE EXPERT SESSION

ECP and Ruxolitinib combination in severe steroid-refractory acute GvHD - Prof. Nikolaus Kröger, University Medical Center Hamburg-Eppendorf, Germany

Thursday 24th October 18:00 – 18:30

The winner of the Mallinckrodt 2024 Advancing ECP Immunomodulation Investigator Award: 30 Years of ECP in Graft versus Host Disease. Refining THERAKOS ECP Immunomodulation™ will be announced at 18.20

Find out more >

If you were unable to join us at EBMT 2024, you can now watch the GvHD Hub EBMT symposium 2024: 30 years of ECP in GvHD: Recommendations for the treatment of cGvHD video series online.

(Symposium supported through an unrestricted educational grant by Therakos – Mallinckrodt)

ECP for chronic GvHD: Patient eligibility, treatment optimization, and follow-up

ZINAIDA PERIC

View Symposium >

Symposium: The Long-Term Burden of Chronic GvHD

The long-term burden of cGvHD

BIPIN SAVANI

View Symposium >

A brief overview and history of ECP

MOHAMAD MOHTY

View Symposium >

Symposium: Early Intervention and Use of ECP Combinations

Early intervention and use of ECP combinations in cGvHD

FLORENT MALARD

View Symposium >

Announcing our partnership with the GvHD Hub

GvHD Hub offers a unique platform for independent, up-to-date medical education and resources on GvHD. Therakos are proud to partner with them in 2024 as platinum sponsors.*

VISIT THE GVHD HUB

Don’t forget to follow us for the latest on our events. More dates will be added soon, and throughout the year.

You can read more about our educational initiatives on our Therakos Institute page.

*This partnership is supported through an unrestricted educational grant.

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

Indications

The THERAKOS™ CELLEX™ Photopheresis System is indicated for patients older than 18 years of age for the administration of photopheresis in the following:

Cutaneous T Cell Lymphoma (CTCL)
Solid Organ Transplant Rejection (SOT) (heart, lung)

The THERAKOS™ CELLEX™ Photopheresis System is indicated in patients older than 3 years of age for the management of:

Acute and Chronic Graft versus Host Disease (aGvHD, cGvHD)

Contraindications

THERAKOS^TM Photopheresis is contraindicated in:

Patients possessing a specific history of a light sensitive disease
Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm³
Patients who have coagulation disorders or who have previously had a splenectomy

Warnings and Precautions

THERAKOS^TMPhotopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure.

Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
When prescribing and administering THERAKOS Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
Treatment frequency exceeding labelling recommendations may result in anaemia.
Venous access carries a small risk of infection and pain.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS

Consult the 8-methoxypsoralen (Methoxsalen (20 micrograms / mL)) professional leaflet or the oral 8-methoxypsoralen formulation package insert before prescribing or dispensing any medication.

Warnings and Precautions

Patients exhibiting multiple basal cell carcinomas or having a history of basal cell carcinoma should be diligently observed and treated.
Methoxsalen may cause fetal harm when given to a pregnant woman. Women undergoing photopheresis should be advised to avoid becoming pregnant.
Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

30 YEARS OFTHERAKOS ECP IMMUNOMODULATIONTMTREATING GvHD

Celebrating three decades of THERAKOS ECP ImmunomodulationTM for GvHD patients

2024 programme and announcements

EBMT 2024 - Industry Symposium

30 years of ECP in GvHD: Recommendations for the treatment of cGvHD

EBMT 2024 - Nurse Symposium

30 Years of ECP – Patient-centered therapy using Therakos ECP technology, then, now and in the future

COSTEM 2024: THERAKOS MEET THE EXPERT SESSION

ECP and Ruxolitinib combination in severe steroid-refractory acute GvHD - Prof. Nikolaus Kröger, University Medical Center Hamburg-Eppendorf, Germany

If you were unable to join us at EBMT 2024, you can now watch the GvHD Hub EBMT symposium 2024: 30 years of ECP in GvHD: Recommendations for the treatment of cGvHD video series online.

ECP for chronic GvHD: Patient eligibility, treatment optimization, and follow-up

The long-term burden of cGvHD

A brief overview and history of ECP

Early intervention and use of ECP combinations in cGvHD

Announcing our partnership with the GvHD Hub

Don’t forget to follow us for the latest on our events. More dates will be added soon, and throughout the year.

You can read more about our educational initiatives on our Therakos Institute page.

Welcome to the Home of ECP

You are leaving the Therakos.eu website.

IMPORTANT SAFETY INFORMATION FOR THE THERAKOS™ PHOTOPHERESIS PROCEDURE

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOSTM PHOTOPHERESIS

30 YEARS OF
THERAKOS ECP IMMUNOMODULATION^TM
TREATING GvHD

Celebrating three decades of THERAKOS ECP Immunomodulation^TM for GvHD patients

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOS^TM PHOTOPHERESIS